09996 PEIJIA-B
- 3.370
- -0.290-7.92%
PEIJIA-B News
As trading resumes, Peijia Medical-B(09996), which is approaching its cash red line, is launching a "maintain liquidity" battle. How many tricks does it still have?
On June 17, Peijia Medical's stock price, which had recovered liquidity, continued to fall under the drag of panicked outflows, and the stock price fell to a record low of 3.36 Hong Kong dollars since its listing. Due to missing the April stock market rally in the pharmaceutical industry in Hong Kong, Peijia Medical's market cap has reached a historic low, and it is about to launch the company's "Hong Kong stock defense war".
Express News | Peijia Medical Reports Audited 2023 Financial Results and Resumes Trading
HKEX In Focus: Peijia Medical-B (09996) resumed trading with a rise of over 5%. The 2023 annual performance has been audited and the year-on-year loss narrowed by 3.7%.
After the resumption of trading this morning, Peijia Medical-B (09996) rose and as of press time, increased by 5.74%, to HKD 3.87, with a turnover of HKD 5.87 million.
The 2023 annual performance of Peijia Medical - B (09996) is the same as the unaudited annual performance disclosed. Resumption of trading on June 17th.
Peijia Medical -B (09996) announced that the company's shares will resume trading at 9:00 am on June 17, 2024.
PEIJIA Medical -B (09996.HK) resumed trading this morning.
Peijia Medical -B (09996.HK) announced on June 17th that its shares will resume trading at 9:00 am today (6/17/2024).
Peijia Medical-B (09996): Resumes trading on June 17.
Paijia Medical -B (09996) announced that its 2023 annual performance has been audited and verified in accordance with the International Auditing and Assurance Standards Board ...
PEIJIA-B: (1) AUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023; AND (2) RESUMPTION OF TRADING
Peijia Medical (09996.HK) will hold a board of directors meeting on June 15 to approve the annual performance.
On June 14, Gelonhui announced that Peijia Medical (09996.HK) will hold another board of directors meeting on June 15, 2024 to consider and approve the audited annual performance of the group for the year ending December 31, 2023, and to consider proposing the distribution of final dividends (if any).
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
Peijia Medical Limited (HKG:9996) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
To the annoyance of some shareholders, Peijia Medical Limited (HKG:9996) shares are down a considerable 28% in the last month, which continues a horrid run for the company. For any long-term shareh
Peijia Healthcare (09996.HK) was suspended due to financial asset evaluation, business operations were normal, and unaudited performance was improving
On April 2, Peijia Healthcare (09996.HK) issued an announcement stating that since the company is discussing the valuation of financial assets with the auditor (initial investment cost is HK$80 million) and is still awaiting certain information and supporting documents, the company will delay issuing the annual results announcement and suspend stock trading from April 2, pending publication of the audited annual results. It is worth noting that the 2023 annual results release deadline set by the Hong Kong Stock Exchange last Thursday has passed. Pegasus Healthcare is only one of many companies, such as Country Garden, Novartis Health, Hongjiu Fruit, and Yida China, which failed to release the audited results announcements in a timely manner. Moreover, it is only because
The results for the full year of 2023 were announced. What was the performance of innovative medical device companies under the collection test?
Hengqiang, the strongest in innovative medical devices
Peijia Medical-B (09996.HK) suspended trading this morning
On April 2, Gelonghui Medical-B (09996.HK) announced that trading of the company's shares will be suspended from 9:00 a.m. today (2/4/2024).
Peijia Medical-B (09996) suspended trading on April 2, pending publication of 2023 annual results
According to the Zhitong Finance App, Peijia Medical-B (09996) announced that trading of the company's shares will be suspended on the Hong Kong Stock Exchange Limited from 9:00 a.m. on April 2, 2024, pending publication of the 2023 annual results.
PEIJIA-B: DELAY IN PUBLICATION OF 2023 ANNUAL RESULTS AND SUSPENSION OF TRADING
Peijia Medical Narrows 2023 Loss as Revenue Jumps 76%
Peijia Medical (HKG:9996) narrowed 2023 loss attributable to owners to 392.5 million yuan, or 0.58 yuan per share, from 407.8 million yuan, or 0.61 yuan per share, the year earlier. Revenue rose year
Peijia Medical-B (09996) announced 2023 unaudited results. Shareholders' losses of 393 million yuan narrowed by 3.7% year-on-year
According to the Zhitong Finance App, Peijia Medical-B (09996) disclosed the 2023 unaudited annual results announcement. The company achieved revenue of 441 million yuan (RMB, same below) during the reporting period, an increase of 75.9% over the previous year. Gross profit of 325 million yuan, an increase of 84.7% year over year. The company's owners should have accounted for a loss of 393 million yuan, and the loss narrowed by 3.7% year-on-year. Loss of $0.58 per share. During the reporting period, the neurological intervention business achieved revenue of 256 million yuan, an increase of 78.1% over the previous year, which greatly exceeded expectations. The gross profit of this business increased 83.4% year over year to 166 million yuan. The main reason for generating revenue is
PEIJIA-B: UNAUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Insider Sellers Might Regret Selling Peijia Medical Shares at a Lower Price Than Current Market Value
Peijia Medical Limited's (HKG:9996) stock price has dropped 15% in the previous week, but insiders who sold CN¥11m in stock over the past year have had less luck. Insiders might have been better off
Peijia Medical-B (09996.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Gelonghui, March 15 | Pegasus Medical-B (09996.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the proposed payment of a final dividend (if any).
Analysis
Price Target
No Data
